Cite
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
MLA
Shen, Lin, et al. “[Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for First-Line Treatment of HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: A Phase III, Multi-Center, Randomized Controlled Trial, Chinese Subreport].” Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology], vol. 35, no. 4, Apr. 2013, pp. 295–300. EBSCOhost, https://doi.org/10.3760/cma.j.issn.0253-3766.2013.04.012.
APA
Shen, L., Xu, J., Feng, F., Jiao, S., Wang, L., Li, J., Guan, Z.-Z., Qin, S., Wang, J., Yu, S., Wang, Y., Jin, Y., Tao, M., Zheng, L., & Pan, L. (2013). [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology], 35(4), 295–300. https://doi.org/10.3760/cma.j.issn.0253-3766.2013.04.012
Chicago
Shen, Lin, Jian-ming Xu, Feng-yi Feng, Shun-chang Jiao, Li-wei Wang, Jin Li, Zhong-Zhen Guan, et al. 2013. “[Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for First-Line Treatment of HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: A Phase III, Multi-Center, Randomized Controlled Trial, Chinese Subreport].” Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology] 35 (4): 295–300. doi:10.3760/cma.j.issn.0253-3766.2013.04.012.